Raj Mehra J.D., Ph.D.
Net Worth
Last updated:
What is Raj Mehra J.D., Ph.D. net worth?
The estimated net worth of Dr. Raj Mehra J.D., Ph.D. is at least $3,621,150 as of 1 Dec 2023. He has received compensation worth at least $3,621,150 in Seelos Therapeutics, Inc..
What is the salary of Raj Mehra J.D., Ph.D.?
Dr. Raj Mehra J.D., Ph.D. salary is $724,230 per year as Founder, Chairman, Chief Executive Officer & Pres in Seelos Therapeutics, Inc..
How old is Raj Mehra J.D., Ph.D.?
Dr. Raj Mehra J.D., Ph.D. is 65 years old, born in 1960.
What stocks does Raj Mehra J.D., Ph.D. currently own?
As insider, Dr. Raj Mehra J.D., Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Seelos Therapeutics, Inc. (SEEL) | Founder, Chairman, Chief Executive Officer & Pres | 75,757 | $0 | $0 |
What does Seelos Therapeutics, Inc. do?
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Raj Mehra J.D., Ph.D. insider trading
Seelos Therapeutics key executives
Seelos Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Raj Mehra J.D., Ph.D. (65) Founder, Chairman, Chief Executive Officer & Pres